vs
Dover Corporation（DOV）与达维塔（DVA）财务数据对比。点击上方公司名可切换其他公司
达维塔的季度营收约是Dover Corporation的1.7倍（$3.6B vs $2.1B），Dover Corporation净利率更高（13.4% vs 6.5%，领先7.0%），Dover Corporation同比增速更快（12.5% vs 12.3%），过去两年达维塔的营收复合增速更高（6.6% vs -1.8%）
美国工业产品综合性制造集团，1955年成立，总部位于伊利诺伊州唐纳斯格罗夫。旗下业务分为工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术五大板块，为标普500指数成分股，纽交所交易代码DOV，2024年位列财富榜单第448位。
达维塔是美国肾脏透析服务提供商，在美国运营2675家门诊中心，服务20.08万名患者；同时在其他11个国家布局367家门诊中心，服务4.94万名患者。公司主要服务终末期肾病患者，这类患者除非接受捐肾移植，否则通常需要终生每周接受三次透析治疗。
DOV vs DVA — 直观对比
营收规模更大
DVA
是对方的1.7倍
$2.1B
营收增速更快
DOV
高出0.2%
12.3%
净利率更高
DOV
高出7.0%
6.5%
两年增速更快
DVA
近两年复合增速
-1.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.1B | $3.6B |
| 净利润 | $282.1M | $234.2M |
| 毛利率 | 39.1% | — |
| 营业利润率 | 16.5% | 15.5% |
| 净利率 | 13.4% | 6.5% |
| 营收同比 | 12.5% | 12.3% |
| 净利润同比 | 22.2% | 43.8% |
| 每股收益（稀释后） | $2.06 | $3.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOVDVA
| Q1 26 | $2.1B | $3.6B | ||
| Q4 25 | $2.1B | $3.6B | ||
| Q3 25 | $2.1B | $3.4B | ||
| Q2 25 | $2.0B | $3.4B | ||
| Q1 25 | $1.9B | $3.2B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $2.0B | $3.3B | ||
| Q2 24 | $2.2B | $3.2B |
净利润DOVDVA
| Q1 26 | $282.1M | $234.2M | ||
| Q4 25 | $282.1M | $234.2M | ||
| Q3 25 | $302.0M | $150.3M | ||
| Q2 25 | $279.1M | $199.3M | ||
| Q1 25 | $230.8M | $162.9M | ||
| Q4 24 | $1.4B | $259.3M | ||
| Q3 24 | $347.1M | $214.7M | ||
| Q2 24 | $281.8M | $222.7M |
毛利率DOVDVA
| Q1 26 | 39.1% | — | ||
| Q4 25 | 39.1% | — | ||
| Q3 25 | 40.1% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 40.0% | — | ||
| Q4 24 | 41.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 37.7% | — |
营业利润率DOVDVA
| Q1 26 | 16.5% | 15.5% | ||
| Q4 25 | 16.5% | 15.5% | ||
| Q3 25 | 18.2% | 14.8% | ||
| Q2 25 | 17.3% | 15.9% | ||
| Q1 25 | 15.9% | 13.6% | ||
| Q4 24 | 14.0% | 17.2% | ||
| Q3 24 | 16.8% | 16.4% | ||
| Q2 24 | 17.0% | 15.9% |
净利率DOVDVA
| Q1 26 | 13.4% | 6.5% | ||
| Q4 25 | 13.4% | 6.5% | ||
| Q3 25 | 14.5% | 4.4% | ||
| Q2 25 | 13.6% | 5.9% | ||
| Q1 25 | 12.4% | 5.1% | ||
| Q4 24 | 96.4% | 7.9% | ||
| Q3 24 | 17.5% | 6.6% | ||
| Q2 24 | 12.9% | 7.0% |
每股收益（稀释后）DOVDVA
| Q1 26 | $2.06 | $3.22 | ||
| Q4 25 | $2.06 | $3.22 | ||
| Q3 25 | $2.19 | $2.04 | ||
| Q2 25 | $2.02 | $2.58 | ||
| Q1 25 | $1.67 | $2.00 | ||
| Q4 24 | $10.38 | $3.08 | ||
| Q3 24 | $2.51 | $2.50 | ||
| Q2 24 | $2.04 | $2.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $700.7M |
| 总债务越低越好 | $3.3B | $10.2B |
| 股东权益账面价值 | $7.4B | $-651.1M |
| 总资产 | $13.4B | $17.5B |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资DOVDVA
| Q1 26 | — | $700.7M | ||
| Q4 25 | — | $700.7M | ||
| Q3 25 | — | $736.5M | ||
| Q2 25 | — | $739.4M | ||
| Q1 25 | — | $511.9M | ||
| Q4 24 | — | $846.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $437.2M |
总债务DOVDVA
| Q1 26 | $3.3B | $10.2B | ||
| Q4 25 | $3.3B | $10.2B | ||
| Q3 25 | $3.1B | $10.2B | ||
| Q2 25 | $3.1B | $10.1B | ||
| Q1 25 | $3.0B | $9.6B | ||
| Q4 24 | $2.9B | $9.2B | ||
| Q3 24 | $3.0B | $9.3B | ||
| Q2 24 | $3.0B | $8.5B |
股东权益DOVDVA
| Q1 26 | $7.4B | $-651.1M | ||
| Q4 25 | $7.4B | $-651.1M | ||
| Q3 25 | $7.7B | $-571.9M | ||
| Q2 25 | $7.4B | $-369.6M | ||
| Q1 25 | $7.1B | $-267.1M | ||
| Q4 24 | $7.0B | $121.1M | ||
| Q3 24 | $5.7B | $386.7M | ||
| Q2 24 | $5.4B | $632.9M |
总资产DOVDVA
| Q1 26 | $13.4B | $17.5B | ||
| Q4 25 | $13.4B | $17.5B | ||
| Q3 25 | $13.4B | $17.6B | ||
| Q2 25 | $13.2B | $17.5B | ||
| Q1 25 | $12.6B | $17.1B | ||
| Q4 24 | $12.5B | $17.3B | ||
| Q3 24 | $11.9B | $17.5B | ||
| Q2 24 | $11.3B | $17.0B |
负债/权益比DOVDVA
| Q1 26 | 0.45× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.42× | 75.76× | ||
| Q3 24 | 0.53× | 23.95× | ||
| Q2 24 | 0.55× | 13.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
